Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197367 | 0.94 | SMN1; SMN2 (0.52) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL5314804 | 0.92 | KMT2A (0.46) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3534158 | 0.88 | RAB9A (0.56) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL2969471 | 0.88 | ALDH1A1 (0.52) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL1697621 | 0.87 | MAPT (0.67) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6377931 | 0.87 | KMT2A (0.57) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL657693 | 0.85 | CHEK1 (0.53) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL22955262 | 0.85 | KMT2A (0.52) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL8789817 | 0.84 | SMN1; SMN2 (0.51) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL224201 | 0.83 | KMT2A (0.50) | KMT2ASMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-1802586-B1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1802586-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006044823-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | KMT2A 1492/4885SMN1; SMN2 4236/4885NPC1 1193/4885 |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | IRAK3, IRAK1, MAP3K1 | KMT2A 1492/4885SMN1; SMN2 4236/4885NPC1 1193/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | KMT2A 1204/4885SMN1; SMN2 4067/4885NPC1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.